Early activity of JANX007 in prostate cancer sees Janux stock gain 190%.

A look at big oncology deals since 2016 finds outright success stories hard to come by. 

Crossover hits overall survival, pouring doubts on the group’s deal hopes.

The study of Novartis’s Pluvicto in pre-chemo prostate cancer is a bust on overall survival, with questions raised about trial design.

Leaked data ahead of the ESMO late breaker show a progression-free survival benefit that looks practice-changing.

The company’s radiopharmaceutical PNT2002 faces a major fourth-quarter catalyst, and US filing could follow.